Apellis Pharmaceuticals, Inc. (FRA:1JK)

Market Cap	2.32B
Revenue (ttm)	866.28M
Net Income (ttm)	38.34M
Shares Out	n/a
EPS (ttm)	0.31
PE Ratio	60.62
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	7
Open	17.95
Previous Close	17.92
Day's Range	17.95 - 17.96
52-Week Range	13.88 - 33.05
Beta	n/a
RSI	49.75
Earnings Date	Feb 25, 2026

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 710
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1JK

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Financial numbers in USD